Annual Rate of Coronary Artery Calcification With PCSK9 Inhibitor Plus Statin Versus Statin Monotherapy

This small study asked whether adding a PCSK9 inhibitor to a statin slows the buildup of coronary calcium more than a statin alone.

It reported that annual calcium progression was lower with the combination (14.3 percent) than with statin monotherapy (29.7 percent), suggesting the intensive LDL lowering of PCSK9 inhibition might stabilize plaque more effectively.

Two cautions are important. First, the study is small and retrospective, so confounding and selection effects loom large. Second — and more subtly — coronary calcium is a tricky surrogate: aggressive lipid lowering can increase calcium density as plaque stabilizes, so “less calcium progression” is not a clean readout of benefit. The relationship between calcium change and outcomes under intensive therapy is genuinely complex.

We rate the evidence limited. It is a small, retrospective study using an ambiguous surrogate; it is hypothesis-generating at best and far weaker than the hard-outcome PCSK9 trials (FOURIER, ODYSSEY) that actually establish the drugs’ benefit.